Subgrouping rarer cancers and clinical trial design

Bruce Johnson, MD, from Dana-Farber Cancer Institute, Boston, MA, explains the challenges associated with developing clinical trials for patients with rarer solid tumors, including defining subgroups of patients for specific therapeutic approaches and recruiting sufficient numbers of participants. Recorded at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Share this video  
Similar topics